...
首页> 外文期刊>Endocrine-related cancer >Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue
【24h】

Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue

机译:与正常甲状旁腺组织相比,microRNA在人甲状旁腺癌中的差异表达

获取原文
           

摘要

Parathyroid carcinoma (PaC) is a rare cause of primary hyperparathyroidism. Though the loss of the oncosuppressor CDC73/HRPT2 gene product, parafibromin, has been involved in the hyperparathyroidism–jaw tumor syndrome and in a consistent set of sporadic PaCs, parathyroid carcinogenesis remains obscure. MicroRNAs are a new class of small, non-coding RNAs implicated in development of cancer, since their deregulation can induce aberrant expression of several target genes. The aim of the present study was to identify differentially expressed microRNAs in parathyroid cancers compared with normal tissues. We performed a TaqMan low-density array profiling of four parathyroid cancers harboring CDC73 inactivating mutations and negative for parafibromin immunostaining. Their microRNA profiling was compared with that of two normal parathyroid biopsies. Out of 362 human microRNAs assayed, 279 (77%) were successfully amplified. Fourteen and three microRNAs were significantly down- and over-expressed in parathyroid cancers respectively. Of these, miR-296 and miR-139 were down-regulated, and miR-503 and miR-222 were over-expressed with a null false discovery rate. Carcinomas could be discriminated from parathyroid adenomas by a computed score based on the expression levels of miR-296, miR-222, and miR-503 as miR-139 was similarly down-regulated in both cancers and adenomas. Finally, miR-296 and miR-222 levels negatively correlated with mRNA levels of the hepatocyte growth factor receptor-regulated tyrosine kinase substrate and p27/kip1 levels respectively. These results suggest the existence of an altered microRNA expression pattern in PaCs together with a potential role of miR-296 as novel oncosuppressor gene in these neoplasia.
机译:甲状旁腺癌(PaC)是原发性甲状旁腺功能亢进症的罕见原因。尽管抑癌药CDC73 / HRPT2基因产物parafibromin的丢失与甲状旁腺功能亢进症-下颌肿瘤综合征和一连串的散发的PaCs有关,但甲状旁腺癌变仍然不明显。 MicroRNA是一类新型的小型非编码RNA,与癌症的发展有关,因为它们的失调可以诱导多个靶基因的异常表达。本研究的目的是鉴定与正常组织相比在甲状旁腺癌中差异表达的微小RNA。我们对四种携带CDC73失活突变且副纤蛋白免疫染色阴性的甲状旁腺癌进行了TaqMan低密度阵列分析。将他们的microRNA分析与两次正常的甲状旁腺活检进行了比较。在测定的362种人类microRNA中,成功扩增了279种(77%)。在甲状旁腺癌中,分别有14和3个microRNA显着降低和过表达。其中,miR-296和miR-139被下调,miR-503和miR-222被过表达,虚假发现率无效。可以根据miR-296,miR-222和miR-503的表达水平通过计算得分将甲状腺癌与甲状旁腺腺瘤区分开来,因为在癌症和腺瘤中miR-139的表达均下调。最后,miR-296和miR-222水平分别与肝细胞生长因子受体调节的酪氨酸激酶底物的mRNA水平和p27 / kip1水平负相关。这些结果表明PaCs中存在微小RNA表达模式的改变,以及miR-296作为这些赘生物中新的抑癌基因的潜在作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号